NexGel (NexGel) Cash, Cash Equivalents, Marketable Securities : $2.42 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexGel Cash, Cash Equivalents, Marketable Securities?

NexGel's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($3.27 Mil) to Dec. 2023 ($2.70 Mil) but then stayed the same from Dec. 2023 ($2.70 Mil) to Mar. 2024 ($2.42 Mil).

NexGel's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($13.35 Mil) to Dec. 2022 ($6.61 Mil) and declined from Dec. 2022 ($6.61 Mil) to Dec. 2023 ($2.70 Mil).

NexGel Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for NexGel's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexGel Cash, Cash Equivalents, Marketable Securities Chart

NexGel Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

0.26

0.03

13.35

6.61

2.70

NexGel Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															5.80	4.30	3.27	2.70	2.42

NexGel Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

NexGel (NAS:NXGL) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

NexGel Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of NexGel's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

NexGel (NexGel) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047

Website

https://www.nexgel.com

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing.

Executives

Steven Mark Glassman	director	99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein	director	QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Scott Robert Henry	director	34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky	director	850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Yaakov Spinrad	director	3450 OAKTON ST, SKOKIE IL 60076
Drapczuk Adam E Iii	officer: Chief Financial Officer	6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc	10 percent owner	C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
Adam R. Levy	officer: CEO and President	2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
David Ian Johnson	director, officer: Chief Executive Officer	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc.	10 percent owner	100 PINE ST., STE. 500, SAN FRANCISCO CA 94111